I will call this meeting to order.
Welcome. We are resuming meeting number 34 of the House of Commons Standing Committee on Health.
Today's meeting is taking place in a hybrid format, pursuant to the Standing Orders.
I would like to remind participants of the following points.
Please wait until I recognize you by name before speaking. For those participating by video conference, please click on the microphone icon to activate your mic, and please mute yourself when you are not speaking. At the bottom of the screen, you can select the appropriate channel for interpretation: floor, English or French. I remind you that all comments should be addressed through the chair. For members in the room, if you wish to speak, please raise your hand. For members on Zoom, please use the “raise hand” function. The clerk and I will manage the speaking order as best we can, and we appreciate your patience and understanding in this regard.
Before we begin, I would like to quote section 20.110 of House of Commons Procedure and Practice, which states:
In the event of disorder, the Chair may suspend the meeting until order can be restored or, if the situation is considered to be so serious as to prevent the committee from continuing with its work, the meeting may be adjourned. In addition, the Chair may, at their discretion, interrupt a member whose observations and questions are repetitive or are unrelated to the matter before the committee. If the member in question persists in making repetitive or off-topic comments, the Chair can give the floor to another member. If the member refuses to yield the floor and continues talking, the Chair may suspend or adjourn the meeting.
I would like to thank the clerk, the analysts and the interpreters for being of assistance in difficult circumstances at this committee.
Pursuant to Standing Order 108(2) and the motion adopted by the committee on Tuesday, September 23, 2025, the committee shall resume its study of Canada's pharmaceutical sovereignty.
The committee suspended its meeting on Tuesday, May 26, during the debate. Therefore, we are resuming this meeting and debate on the motion by Dr. Eyolfson, with the amendment moved by Dr. Strauss, which is as follows: “That the motion be amended by adding the following: Whereas e-prescription services held the promise of improving prescribed practices as pertains to HIV medicines, that Michael Green, the former chief executive officer of Canada Health Infoway, appear before the committee during the study for no less than two hours to testify on his role in the implementation and oversight of the Liberal government's failed $300-million PrescribeIT program.”
Did all honourable members get the motion circulated in both official languages? If not, please raise your hand now.
I see that everyone got it.
I have reviewed the text of this amendment, and I have deemed it to be out of scope. Therefore, I rule this amendment to be inadmissible.
We will now go back to the motion.